USP <1117> "Microbial Best Laboratory Practices": An Interview with Scott Sutton - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP <1117> "Microbial Best Laboratory Practices": An Interview with Scott Sutton
Scott Sutton discusses the current state of USP 91117: and USP's plans for future revisions.


Pharmaceutical Technology


PharmTech: Who should be aware of the principles stated in USP ‹1117›?

Sutton: The principles stated in USP ‹1117› are important for the integrity of the data coming from the QC microbiology lab. All personnel working in that laboratory should be familiar with these principles, as should the QA unit responsible for reviewing the data and auditing the lab. It should also be noted that internationally regulatory agencies are certainly familiar with this chapter, and so all those responsible for product submissions, regulatory inspections and relationships with those agencies should be aware of current expectations.

PharmTech: Why is training, particularly of supervisors, such a concern in this chapter?

Sutton: You would like the situation to be that everybody in the microbiology laboratories work for people who are well-trained and academically trained microbiologists. Unfortunately the common situation in a lot of laboratories is that the person who heads up the microbiology laboratory may have not have any training in microbiology at all. And that is reflected in how the laboratory operates. You can't run a lab the way you run a chemistry lab. Microbiology labs should be headed by someone who really knows the scientific discipline, not only for the confidence you have in the results but also the fundamental biosafety requirements. The biosafety manual published by the Centers for Disease Control requires all Level 2 laboratories to be led by a microbiologist who is able to set safety rules and guidelines. But in the industry today, this is not true for many microbiology laboratories. So this provides a minimal set of requirements.

PharmTech: What other situations in the industry has created a need for this chapter?

Sutton: I would refer you to a recent publication by Luis Jimenez (J. Jimenez, "Microbial Diversity in Pharmaceutical Product Recalls and Environments," PDA J Pharm Sci Tech. 61 (5), 383-398 [2007]). He published an interesting retrospective on recalls over the past years looking at both sterile and nonsterile product recalls. There are a large number of those recalls from the smaller pharmaceutical companies. It should be noted that some companies do not have a microbiology department at all and send all microbiology testing out-of-house for testing. The danger in this approach is that the company fails to develop the in-house expertise in microbiology, and may run risks that other companies might avoid. The quality of safeguarding the finished product has a large, and a critical microbiology component.

PharmTech: What are the revisions that need to be made?

Sutton: There have been a couple of gaps that have been identified in the chapter that should be corrected. One deals with sample handling and transport, which is especially useful for samples going out to contract laboratories. There is nothing in the chapter right now that discusses how to collect samples for shipping and transport, how much time is permissible between sample collection and sample testing. These issues should be addressed. Additional information needs to be included on equipment (especially lab autoclaves) and on laboratory resources. In addition, the section on supervision of the laboratory may also be strengthened, depending on the comments we receive after the publication in the Pharmacopeial Forum. So we are hoping those in industry will be active in this ongoing revision process.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here